Understanding lipid profiles in adult sickle cell patients
Study of Lipid Balance in Adult Sickle Cell SS or SC Patients at Steady State and According to Clinical Phenotypes and During Acute Complications Acronym : "HDL2"
This study is trying to see how fat levels in the blood affect adults with sickle cell disease and their related health issues in the French West Indies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 2 sites (Pointe-à-Pitre, Guadeloupe and 1 other locations) |
| Trial ID | NCT05780775 on ClinicalTrials.gov |
What this trial studies
This study investigates lipid profiles in adult patients with sickle cell disease living in the French West Indies. It aims to analyze the relationship between lipid levels and various complications associated with sickle cell disease, such as vasoocclusive crises and pulmonary arterial hypertension. The study will collect medical histories and perform blood tests over a four-year period to observe changes in lipid profiles and identify genetic factors influencing these complications. The research will also explore insulin resistance and lipid functionality in specific patient subgroups.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over with sickle cell anemia or SC sickle cell disease living in Guadeloupe or Martinique.
Not a fit: Patients with other hemoglobinopathies, those who are pregnant or lactating, or those recently hospitalized for transfusion or bleeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of sickle cell disease by identifying lipid-related risk factors for complications.
How similar studies have performed: While studies on lipid profiles in sickle cell disease are limited, similar research has shown potential associations between lipid levels and disease complications, suggesting this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged from 18 years and over * Be affected with Sickle cell anemia or SC sickle cell * Living in French Caribbean Islands of Guadeloupe or Martinique and followed by physicians issued from a French West Indies Sickle Cell Reference or Competence Center * At steady state in the last month (without acute complication) * To have given a written consent after information on the study. Exclusion Criteria: * Other hemoglobinopathies than sickle cell disease * Pregnancy or lactation * Patient under judicial protection or without freedom * Patient not affiliated with a social security system * Patient hospitalized for transfusion or bleeding in the last 3 months
Where this trial is running
Pointe-à-Pitre, Guadeloupe and 1 other locations
- Unité Transversale de la Drépanocytose — Pointe-à-Pitre, Guadeloupe, France (Recruiting)
- Centre de Référence de la Drépanocytose — Le Lamentin, Martinique, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Marie-Laure LALANNE-MISTRIH — : University Hospital of Guadeloupe - Department of Nutrition
- Study coordinator: Valérie HAMONY-SOTER
- Email: valerie.soter@chu-guadeloupe.fr
- Phone: +590 590934686
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.